INCY

Incyte Corp

116.39

Oct 21 • 8:28 AM ET -0.22 (-0.19%)

Healthcare Biotechnology USA Large NASD

Peers: ARQT EXEL JAZZ REGN GMAB GSK ONC NVS BMY ABBV

| Held by: VTI VOO VB VBK IVV SPY RSP IBB XLV XBI

Index	S&P 500
Market Cap	23.59B
Enterprise Value	19.09B
Income	1.61B
Sales	5.82B
Book/sh	31.57
Cash/sh	22.38
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	2844
IPO	Nov 04, 1993

P/E	14.83
Forward P/E	14.31
PEG	1.49
P/S	4.05
P/B	3.69
P/C	5.20
P/FCF	12.28
EV/EBITDA	9.85
EV/Sales	3.28
Quick Ratio	4.51
Current Ratio	4.59
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	7.85
EPS next Y	8.13
EPS next Q	-3.64
EPS this Y	-53.30%
EPS next Y	156.01%
EPS next 5Y	9.59%
EPS past 3/5Y	61.53% -
Sales past 3/5Y	14.84% 14.03%
EPS Y/Y TTM	80.66%
Sales Y/Y TTM	26.93%
EPS Q/Q	38.02%
Sales Q/Q	37.72%
Earnings	Oct 29 BMO
EPS/Sales Surpr.	40.72% 11.31%

Insider Own	0.91%
Insider Trans	-9.50%
Inst Own	103.44%
Inst Trans	-1.18%
ROA	23.55%
ROE	30.67%
ROIC	25.30%
Gross Margin	91.42%
Oper. Margin	31.61%
Profit Margin	27.71%
SMA20	0.33%
SMA50	-4.20%
SMA200	8.05%
Trades

Shs Outstand	200.98M
Shs Float	200.84M
Short Float	4.97%
Short Ratio	6.10
Short Interest	9.99M
52W High	132.60 -12.22%
52W Low	84.02 38.53%
Volatility	2.81% 2.80%
ATR (14)	3.70
RSI (14)	48.42
Beta	0.78
Rel Volume	0.06
Avg Volume	1.64M
Volume	5,043

Perf Week	4.32%
Perf Month	-8.30%
Perf Quarter	-0.26%
Perf Half Y	20.31%
Perf YTD	17.84%
Perf Year	33.32%
Perf 3Y	111.12%
Perf 5Y	76.70%
Perf 10Y	32.68%
Recom	2.29
Target Price	131.48
Prev Close	116.61
Price	116.39
Change %	-0.19%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-26	Resumed	Morgan Stanley	Equal-Weight	$119
Aug-20-26	Initiated	Canaccord Genuity	Buy	$152
Jun-22-26	Upgrade	BMO Capital Markets	Underperform → Market Perform	$94
May-22-26	Initiated	Bernstein	Mkt Perform	$99
Mar-16-26	Downgrade	Jefferies	Buy → Hold	$94
Feb-05-26	Initiated	H.C. Wainwright	Buy	$135
Jan-20-26	Downgrade	Wells Fargo	Overweight → Equal Weight	$107
Dec-08-25	Upgrade	Mizuho	Neutral → Outperform	$121
Nov-03-25	Upgrade	Guggenheim	Neutral → Buy	$125
Oct-08-25	Downgrade	Oppenheimer	Outperform → Perform
Aug-06-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$89
Aug-01-25	Initiated	Barclays	Overweight	$90
Jun-16-25	Upgrade	Stifel	Hold → Buy	$107
Mar-18-25	Downgrade	William Blair	Outperform → Mkt Perform
Mar-18-25	Downgrade	Guggenheim	Buy → Neutral
Dec-17-24	Initiated	UBS	Neutral	$77
Oct-29-24	Upgrade	BofA Securities	Neutral → Buy	$68 → $90
Oct-01-24	Initiated	Wolfe Research	Outperform	$84
Sep-18-24	Downgrade	Truist	Buy → Hold	$83 → $74
Jul-02-24	Downgrade	BMO Capital Markets	Market Perform → Underperform	$52 → $48

Show Previous Ratings

Oct-18-26 06:05PM	Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 (Business Wire)
Oct-09-26 11:36AM	Is Vertex Stock Worth More Than Its Competitors? (Trefis)
Oct-08-26 08:00AM	Incyte to Report Third Quarter Financial Results (Business Wire)
Sep-28-26 06:13AM	Mirum and Incyte's Atebrioz approved for FOP in US (Pharmaceutical Business Review)
Sep-25-26 07:00PM	Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva (Business Wire)
02:43PM	Loading…
02:43PM	INCY, MIRM Slip Into FDAs Weekend Decision Date On Shared Rare-Disease Pill (Stocktwits)
Sep-23-26 08:28AM	6 'Moonshot' Biotech Stocks That Offer Big Risks, Bigger Rewards (Barrons.com)
Sep-22-26 08:30AM	Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte's Inflammation and Autoimmunity Portfolio (Business Wire)
Sep-21-26 07:06AM	FDA Decision Watch: MRK, MIRM, INCY, GRAL Face Key Regulatory Catalysts This Week (Stocktwits)
Sep-19-26 08:02AM	Robinhood Soars, SpaceX Orbits Entry: Five Stocks Near Buy Points (Investor's Business Daily)
Sep-17-26 06:44PM	MIRM, INCY Stocks In Focus Will A September 26 FDA Ruling Reward This Weeks Gains? (Stocktwits)
Sep-11-26 08:04AM	Profitable Biotech Incyte Forms Handle As Institutional Buyers Load Up On Stock (Investor's Business Daily)
Sep-01-26 08:00AM	Incyte to Present at Upcoming Investor Conferences (Business Wire)
Aug-20-26 01:46AM	7 Growth Stocks Holding Up in a Tough Market (Barrons.com)
Aug-12-26 12:38PM	Incyte Sales Growth Drives Share Price Gains (FX Empire)
04:30PM	Loading…
Aug-07-26 04:30PM	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-29-26 01:22PM	Incyte Shares Retreat After Best Day In A Year Despite Opzelura EU Nod (Stocktwits)
06:00AM	Opzelura (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis (Business Wire)
Jul-28-26 04:30PM	Incyte Corp. stock outperforms competitors on strong trading day (MarketWatch) +9.30%
03:01PM	Incyte Corp (INCY) Q2 2026 Earnings Call Highlights: Robust Revenue Growth and Strategic ... (GuruFocus.com)
09:29AM	Incyte Tops Second-Quarter Expectations but Shares Slip on Lower Revenue Outlook (InvestorsHub)
07:09AM	Incyte: Q2 Earnings Snapshot (Associated Press)
07:00AM	Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates (Business Wire)
Jul-20-26 11:02AM	Halozyme Signs ENHANZE Collaboration with Incyte for Subcutaneous INCA033989 Development (InvestorsHub)
08:00AM	Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE Technology (PR Newswire)
Jul-17-26 01:10PM	Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers (Business Wire)
Jul-16-26 09:06AM	Collect 9.8% On VRTX Stock Now, And Still Keep 15% Of Upside (Trefis)
Jul-13-26 01:37PM	Own Regeneron For Biotech Growth? Incyte Is Making Its Case. (Trefis)
04:00AM	Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types (Business Wire)
Jul-08-26 08:48AM	Collect 9.0% On VRTX Stock Now, And Still Keep 15% Of Upside (Trefis)
08:00AM	Loading…
08:00AM	Incyte to Report Second Quarter Financial Results (Business Wire)
Jul-06-26 08:39AM	Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio (Business Wire)
Jul-03-26 11:58AM	Incyte Shares Rise on EPS Growth, Lifted Guidance, Expansion (FX Empire)
Jun-26-26 01:49PM	Lilly, J&J and AbbVie Hit New Highs (GuruFocus.com) +5.78%
Jun-22-26 04:30PM	Incyte Corp. stock outperforms competitors on strong trading day (MarketWatch) +5.54%
Jun-15-26 04:30PM	Incyte Corp. stock underperforms Monday when compared to competitors (MarketWatch) -6.04%
09:51AM	Verizon Upgraded, Oracle Downgraded: Updated Rankings on Top Blue-Chip Stocks (InvestorPlace)
Jun-14-26 04:35PM	Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva (Business Wire)
Jun-13-26 11:15AM	Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia (Business Wire)
Jun-11-26 03:56PM	Imviva Unveils Leukemia Data at EHA 2026 With 86% Response Rates (Exec Edge)
01:50PM	Incyte Nears Buy Point As $1.25 Billion Acquisition Expands Offerings (Investor's Business Daily)
Jun-08-26 07:34AM	Incyte to Buy Vega Therapeutics For Up to $2 Billion (The Wall Street Journal)
07:00AM	Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders (Business Wire)
Jun-04-26 08:05AM	Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026 (Business Wire)
Jun-03-26 04:30PM	Incyte Corp. stock outperforms competitors on strong trading day (MarketWatch) +6.22%
Jun-02-26 01:30AM	Centene, Deckers and 14 Other 'Dividend Hopefuls' (Barrons.com)
May-30-26 08:00AM	Incytes Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi/Minjuvi) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL (Business Wire)
May-28-26 04:27PM	JPMorgan says large-cap biotech is back as profits and pipelines fuel upside (Investing.com)
May-26-26 08:00AM	Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference (Business Wire)
May-19-26 08:00AM	Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development (Business Wire)
May-12-26 09:30AM	Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress (Business Wire)
May-07-26 08:50AM	Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis (Business Wire)
May-06-26 04:30PM	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-01-26 05:28PM	Incyte Announces FDA Approval of Jakafi XR (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease (Business Wire)
Apr-29-26 08:00AM	Incyte to Present at Upcoming Investor Conferences (Business Wire)
03:03AM	Incyte Corp (INCY) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Promising ... (GuruFocus.com)
Apr-28-26 12:51PM	Incyte Corporation Q1 2026 Earnings Call Summary (Moby)
09:09AM	Incyte Stock Reverses, Though Questions Face Its Key Growth Product (Investor's Business Daily)
07:11AM	Incyte: Q1 Earnings Snapshot (Associated Press)
07:00AM	Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates (Business Wire)
07:00AM	Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer (Business Wire)
Apr-21-26 10:00AM	Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (Business Wire)
Mar-28-26 03:00PM	Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting (Business Wire)
Mar-25-26 09:00AM	Incyte Announces Executive Leadership Appointments (Business Wire)
Mar-20-26 10:00AM	Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting (Business Wire)
Mar-16-26 09:37AM	Qualcomm, Adobe downgraded: Wall Street's top analyst calls (The Fly)
Mar-09-26 12:11PM	INCY Wins EC Approval for Label Expansion of Oncology Drug Zynyz (Zacks)
Mar-06-26 04:42PM	Incyte Announces the European Commission Approval of Zynyz (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC) (Business Wire)
Mar-02-26 11:43AM	LLY Wins CHMP Nod for Olumiant's Expanded Use in Alopecia Areata (Zacks)
Feb-27-26 08:11AM	Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata (PR Newswire)
Feb-20-26 04:08AM	Incyte Corp. (INCY) Reports Q4 2025 Revenue Growth of 28% to $1.51B Driven by Jakafi and Opzelura Sales (Insider Monkey)
Feb-19-26 09:55AM	Where is Incyte Corporation (INCY) Headed According to Analysts? (Insider Monkey)
Feb-17-26 08:00AM	Incyte to Present at Upcoming Investor Conferences (Business Wire)
12:32AM	The Top 5 Analyst Questions From Incyte's Q4 Earnings Call (StockStory)
Feb-12-26 03:24AM	Do Wall Street Analysts Like Incyte Corporation Stock? (Barchart)
Feb-11-26 09:29AM	Company News for Feb 11, 2026 (Zacks)
01:48AM	Analyst Report: Incyte Corporation (Morningstar Research)
12:32AM	INCY Q4 Deep Dive: Revenue Growth Outpaces Profit as Pipeline Advances, Margins Narrow (StockStory)
Feb-10-26 04:32PM	Broader Market Falls Ahead of Wednesdays US Jobs Report (Barchart) -8.24%
03:50PM	Incyte Q4 Earnings Call Highlights (MarketBeat)
02:03PM	Incyte Corp (INCY) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Pipeline ... (GuruFocus.com)
12:05PM	Why Incyte (INCY) Stock Is Nosediving (StockStory)
11:16AM	Stocks are Mixed After Weak Retail Sales Data Released (Barchart)
10:38AM	INCY Q4 Earnings Miss Estimates, Revenues Beat on Higher Product Sales (Zacks)
10:06AM	Incyte Crumbles As Light Opzelura Guide Undoes Quarterly Sales Beat (Investor's Business Daily)
09:30AM	Incyte (INCY) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
08:15AM	Incyte (INCY) Q4 Earnings Lag Estimates (Zacks)
07:35AM	Incyte (NASDAQ:INCY) Surprises With Q4 CY2025 Sales (StockStory)
07:24AM	Incyte: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Incyte Reports Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Feb-09-26 11:38AM	Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts? (Zacks)
09:40AM	Here's Why Incyte (INCY) is a Strong Value Stock (Zacks)
Feb-08-26 10:07PM	Incyte (INCY) Q4 Earnings: What To Expect (StockStory)
Feb-06-26 08:23AM	Incyte Gears Up to Report Q4 Earnings: Is a Beat in the Cards? (Zacks) +5.48%
Feb-05-26 10:12AM	Microsoft downgraded, Snap upgraded: Wall Street's top analyst calls (The Fly)
09:15AM	Unveiling Incyte (INCY) Q4 Outlook: Wall Street Estimates for Key Metrics (Zacks)
07:58AM	Here Are Thursdays Top Wall Street Analyst Research Calls: CAVA Group, DigitalOcean, Fox Corp, Jack Henry, Microsoft, Qualcomm, Snap, Zoom Communications, and More (24/7 Wall St.)
Feb-04-26 10:00AM	Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy? (Zacks)
08:55AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
08:11AM	TD Cowen Keeps Buy Rating on Incyte (INCY), Cites Roadmap to Triple Non-Jakafi Revenue by 2029 (Insider Monkey)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CAGNONI PABLO J	President, Global Head of R&D	Oct 15 '26	Option Exercise	65.76	2,642	173,742	185,842	Oct 19 04:38 PM
CAGNONI PABLO J	President, Global Head of R&D	Oct 15 '26	Sale	112.71	2,642	297,780	183,200	Oct 19 04:38 PM
PABLO CAGNONI	Officer	Oct 15 '26	Proposed Sale	112.71	2,642	297,780		Oct 15 04:01 PM
CAGNONI PABLO J	President, Global Head of R&D	Sep 15 '26	Option Exercise	66.39	23,218	1,541,331	206,418	Sep 17 04:04 PM
CAGNONI PABLO J	President, Global Head of R&D	Sep 15 '26	Sale	120.49	23,218	2,797,629	183,200	Sep 17 04:04 PM
PABLO CAGNONI	Officer	Sep 15 '26	Proposed Sale	120.49	23,218	2,797,571		Sep 15 04:06 PM
CAGNONI PABLO J	President, Global Head of R&D	Aug 19 '26	Sale	125.56	10,801	1,356,174	183,200	Aug 20 05:15 PM
PABLO CAGNONI	Officer	Aug 19 '26	Proposed Sale	125.56	10,801	1,356,190		Aug 19 04:20 PM
CAGNONI PABLO J	President, Global Head of R&D	Aug 12 '26	Sale	120.04	10,803	1,296,792	194,001	Aug 14 04:01 PM
PABLO CAGNONI	Officer	Aug 12 '26	Proposed Sale	120.04	10,803	1,296,774		Aug 12 04:09 PM
CAGNONI PABLO J	President, Global Head of R&D	Aug 05 '26	Sale	122.69	10,640	1,305,422	204,804	Aug 07 04:02 PM
Mayes Patrick A	EVP & Chief Scientific Officer	Aug 05 '26	Option Exercise	106.47	2,207	234,979	63,648	Aug 07 04:01 PM
Mayes Patrick A	EVP & Chief Scientific Officer	Aug 05 '26	Sale	123.99	2,207	273,646	61,441	Aug 07 04:01 PM
PABLO CAGNONI	Officer	Aug 05 '26	Proposed Sale	122.69	10,640	1,305,450		Aug 05 04:15 PM
PATRICK A MAYES	Officer	Aug 05 '26	Proposed Sale	123.99	2,207	273,646		Aug 05 04:14 PM
CAGNONI PABLO J	President, Global Head of R&D	Jul 31 '26	Sale	119.70	15,888	1,901,794	215,444	Aug 04 04:04 PM
Mayes Patrick A	EVP & Chief Scientific Officer	Jul 31 '26	Option Exercise	74.37	39,712	2,953,496	103,340	Aug 04 04:04 PM
Mayes Patrick A	EVP & Chief Scientific Officer	Aug 03 '26	Option Exercise	105.43	6,055	638,379	67,496	Aug 04 04:04 PM
Mayes Patrick A	EVP & Chief Scientific Officer	Jul 31 '26	Sale	119.46	41,899	5,005,173	61,441	Aug 04 04:04 PM
Mayes Patrick A	EVP & Chief Scientific Officer	Aug 03 '26	Sale	120.43	6,055	729,204	61,441	Aug 04 04:04 PM
PATRICK A MAYES	Officer	Aug 03 '26	Proposed Sale	120.43	6,055	729,204		Aug 03 04:39 PM
PATRICK A MAYES	Officer	Jul 31 '26	Proposed Sale	119.46	41,899	5,005,186		Jul 31 04:59 PM
PABLO CAGNONI	Officer	Jul 31 '26	Proposed Sale	119.70	15,888	1,901,833		Jul 31 04:04 PM
Stein Steven H	CMO & Head of Late-Stage Dev.	Jul 16 '26	Sale	114.73	1,877	215,348	21,118	Jul 20 04:10 PM
Issa Mohamed Khairie	EVP, Head of U.S. Commercial	Jul 16 '26	Sale	115.01	1,093	125,706	63,940	Jul 20 04:09 PM
STEVEN STEIN	Officer	Jul 16 '26	Proposed Sale	114.73	1,877	215,339		Jul 16 04:15 PM
Stein Steven H	CMO & Head of Late-Stage Dev.	Jul 15 '26	Sale	113.05	28,237	3,192,193	26,083	Jul 16 04:07 PM
MOHAMED ISSA	Officer	Jul 16 '26	Proposed Sale	115.01	1,093	125,706		Jul 16 04:04 PM
STEVEN STEIN	Officer	Jul 15 '26	Proposed Sale	113.05	28,237	3,192,255		Jul 15 04:09 PM
Tray Thomas	Principal Accounting Officer	Jun 04 '26	Option Exercise	83.83	2,639	221,227	23,771	Jun 08 04:04 PM
Tray Thomas	Principal Accounting Officer	Jun 04 '26	Sale	100.00	2,639	263,900	21,132	Jun 08 04:04 PM
THOMAS R TRAY	Officer	Jun 04 '26	Proposed Sale	100.00	2,639	263,900		Jun 04 04:03 PM
Tray Thomas	Principal Accounting Officer	May 26 '26	Sale	97.35	2,051	199,665	21,132	May 28 04:03 PM
BIENAIME JEAN JACQUES	Director	May 26 '26	Option Exercise	84.53	15,000	1,267,950	35,841	May 28 04:03 PM
THOMAS R TRAY	Officer	May 26 '26	Proposed Sale	97.35	2,051	199,665		May 26 04:04 PM
Clancy Paul J	Director	May 19 '26	Option Exercise	84.53	15,000	1,267,950	38,741	May 21 04:02 PM
Clancy Paul J	Director	May 19 '26	Sale	94.93	15,000	1,423,950	23,741	May 21 04:02 PM
PAUL J. CLANCY	Director	May 19 '26	Proposed Sale	94.93	15,000	1,424,006		May 19 04:21 PM
BAKER BROS. ADVISORS LP	Director	May 08 '26	Option Exercise	84.53	30,000	2,535,900	28,203,718	May 11 04:45 PM
CAGNONI PABLO J	President, Global Head of R&D	Apr 17 '26	Option Exercise	69.43	18,667	1,296,046	281,359	Apr 21 04:09 PM
CAGNONI PABLO J	President, Global Head of R&D	Apr 17 '26	Sale	96.50	18,667	1,801,366	262,692	Apr 21 04:09 PM
Meury William	Chief Executive Officer	Apr 15 '26	Option Exercise	0.00	125,000	0	161,101	Apr 17 04:13 PM
PABLO CAGNONI	Officer	Apr 17 '26	Proposed Sale	96.50	18,667	1,801,326		Apr 17 04:07 PM
CAGNONI PABLO J	President, R&D	Mar 17 '26	Option Exercise	63.07	18,667	1,177,355	253,467	Mar 19 04:20 PM
CAGNONI PABLO J	President, R&D	Mar 17 '26	Sale	94.24	18,667	1,759,178	234,800	Mar 19 04:20 PM
PABLO CAGNONI	Officer	Mar 17 '26	Proposed Sale	94.24	18,667	1,759,102		Mar 17 04:07 PM
CAGNONI PABLO J	President, R&D	Feb 19 '26	Option Exercise	61.59	18,668	1,149,702	253,468	Feb 23 04:05 PM
CAGNONI PABLO J	President, R&D	Feb 19 '26	Sale	100.91	18,668	1,883,788	234,800	Feb 23 04:05 PM
PABLO CAGNONI	Officer	Feb 19 '26	Proposed Sale	100.91	18,668	1,883,797		Feb 19 04:02 PM
VIJAY IYENGAR	Officer	Feb 09 '26	Proposed Sale	109.00	12,743	1,388,987		Feb 09 05:14 PM
Issa Mohamed Khairie	EVP, Head of US Oncology	Jan 07 '26	Sale	109.07	10,856	1,184,064	66,132	Jan 08 04:03 PM
Stein Steven H	EVP & Chief Medical Officer	Jan 05 '26	Sale	101.70	15,634	1,589,978	34,203	Jan 07 04:03 PM
MOHAMED ISSA	Officer	Jan 07 '26	Proposed Sale	109.07	10,856	1,184,051		Jan 07 04:01 PM
VIJAY IYENGAR	Officer	Jan 06 '26	Proposed Sale	104.35	95,811	9,998,256		Jan 06 04:05 PM
VIJAY IYENGAR	Officer	Jan 05 '26	Proposed Sale	102.81	16,437	1,689,888		Jan 05 04:34 PM
STEVEN STEIN	Officer	Jan 05 '26	Proposed Sale	101.70	15,634	1,589,995		Jan 05 04:06 PM
Tray Thomas	Principal Accounting Officer	Dec 19 '25	Option Exercise	95.76	2,774	265,638	25,747	Dec 22 08:46 PM
Tray Thomas	Principal Accounting Officer	Dec 19 '25	Sale	100.00	2,774	277,400	22,973	Dec 22 08:46 PM
Tray Thomas	Principal Accounting Officer	Dec 18 '25	Sale	98.25	600	58,950	22,973	Dec 22 08:46 PM
VIJAY IYENGAR	Officer	Dec 19 '25	Proposed Sale	101.73	52,941	5,385,677		Dec 19 04:06 PM
THOMAS R TRAY	Officer	Dec 19 '25	Proposed Sale	100.00	2,774	277,400		Dec 19 04:05 PM
THOMAS R TRAY	Officer	Dec 18 '25	Proposed Sale	98.25	600	58,950		Dec 18 04:12 PM
Morrissey Michael James	EVP, Head of Tech. Operations	Dec 16 '25	Sale	97.29	54,008	5,254,547	31,830	Dec 18 04:11 PM
Morrissey Michael James	EVP, Head of Tech. Operations	Dec 17 '25	Sale	97.26	4,323	420,455	27,507	Dec 18 04:11 PM
MICHAEL MORRISSEY	Officer	Dec 17 '25	Proposed Sale	97.26	4,323	420,455		Dec 17 04:01 PM
VIJAY IYENGAR	Officer	Dec 16 '25	Proposed Sale	98.39	13,388	1,317,245		Dec 16 04:53 PM
MICHAEL MORRISSEY	Officer	Dec 16 '25	Proposed Sale	97.29	54,008	5,254,458		Dec 16 04:15 PM
CHRISTIANA STAMOULIS	Officer	Dec 15 '25	Proposed Sale	97.00	187,690	18,205,930		Dec 15 05:31 PM
Mayes Patrick A	EVP & Chief Scientific Officer	Dec 10 '25	Sale	95.58	5,553	530,756	60,266	Dec 12 04:01 PM
Mayes Patrick A	EVP & Chief Scientific Officer	Dec 11 '25	Sale	94.94	255	24,210	60,011	Dec 12 04:01 PM
PATRICK A MAYES	Officer	Dec 11 '25	Proposed Sale	94.94	255	24,210		Dec 11 04:13 PM
VIJAY IYENGAR	Officer	Dec 10 '25	Proposed Sale	95.51	23,104	2,206,695		Dec 10 05:29 PM
PATRICK A MAYES	Officer	Dec 10 '25	Proposed Sale	95.58	5,553	530,756		Dec 10 04:04 PM
Stein Steven H	EVP & Chief Medical Officer	Dec 02 '25	Sale	102.51	20,105	2,060,964	63,129	Dec 03 04:36 PM
Stein Steven H	EVP & Chief Medical Officer	Dec 01 '25	Sale	102.96	2,559	263,475	100,327	Dec 03 04:36 PM
STEVEN STEIN	Officer	Dec 02 '25	Proposed Sale	102.51	20,105	2,060,978		Dec 02 04:04 PM
STEVEN STEIN	Officer	Dec 01 '25	Proposed Sale	102.96	2,559	263,482		Dec 01 04:05 PM
Tray Thomas	Principal Accounting Officer	Nov 24 '25	Sale	103.00	600	61,800	23,573	Nov 25 04:02 PM
Tray Thomas	Principal Accounting Officer	Nov 21 '25	Sale	102.00	169	17,238	24,173	Nov 25 04:02 PM
THOMAS R TRAY	Officer	Nov 24 '25	Proposed Sale	103.00	600	61,800		Nov 24 04:13 PM
THOMAS R TRAY	Officer	Nov 21 '25	Proposed Sale	102.00	169	17,238		Nov 21 04:17 PM
Denton Sheila A.	EVP & General Counsel	Nov 17 '25	Option Exercise	64.25	278	17,862	26,847	Nov 19 04:08 PM
Denton Sheila A.	EVP & General Counsel	Nov 17 '25	Sale	104.36	278	29,012	26,569	Nov 19 04:08 PM
SHEILA DENTON	Officer	Nov 17 '25	Proposed Sale	104.36	278	29,012		Nov 17 04:01 PM
Hoppenot Herve	Director	Nov 10 '25	Sale	105.46	187,500	19,773,750	329,646	Nov 12 04:06 PM
CHRISTIANA STAMOULIS	Officer	Nov 12 '25	Proposed Sale	109.00	7,442	811,178		Nov 12 04:06 PM
HERVE HOPPENOT	Officer	Nov 10 '25	Proposed Sale	105.46	187,500	19,773,454		Nov 10 06:14 PM
Stein Steven H	EVP & Chief Medical Officer	Nov 05 '25	Option Exercise	93.04	5,233	486,868	108,119	Nov 07 04:01 PM
Stein Steven H	EVP & Chief Medical Officer	Nov 05 '25	Sale	102.20	5,233	534,813	102,886	Nov 07 04:01 PM
Denton Sheila A.	EVP & General Counsel	Nov 04 '25	Option Exercise	58.06	598	34,720	27,167	Nov 06 04:01 PM
Denton Sheila A.	EVP & General Counsel	Nov 04 '25	Sale	101.36	598	60,613	26,569	Nov 06 04:01 PM
STEVEN STEIN	Officer	Nov 05 '25	Proposed Sale	102.20	5,233	534,813		Nov 05 04:37 PM
Heeson Lee	EVP, Head of Incyte Intl	Nov 03 '25	Sale	94.02	3,074	289,017	29,241	Nov 05 04:12 PM
SHEILA DENTON	Officer	Nov 04 '25	Proposed Sale	101.36	598	60,613		Nov 04 04:09 PM
CHRISTIANA STAMOULIS	Officer	Nov 03 '25	Proposed Sale	97.74	22,113	2,161,367		Nov 03 04:11 PM
LEE HEESON	Officer	Nov 03 '25	Proposed Sale	94.02	3,074	289,017		Nov 03 04:02 PM
CHRISTIANA STAMOULIS	Officer	Oct 30 '25	Proposed Sale	94.00	14,986	1,408,684		Oct 30 04:31 PM
BARRY FLANNELLY	Officer	Oct 27 '25	Proposed Sale	91.73	33,452	3,068,539		Oct 27 04:21 PM

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded on April 8, 1991 and is headquartered in Wilmington, DE.

CEO & DirectorMr. William J. Meury

Ph.D.Dr. Pablo J. Cagnoni M.D.

Principal Financial OfficerMr. Thomas Tray

Executive VPDr. Steven H. Stein M.D.

Executive Vice President & Head of U.S. CommercialMr. Mohamed Khairie Issa

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INCY

Incyte Corp

Upgrade your Finviz experience